Trials / Completed
CompletedNCT01114581
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Reckitt Benckiser LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mucinex | Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study |
| DRUG | Placebo | Placebo given as 2 tablets |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2010-05-03
- Last updated
- 2018-09-19
- Results posted
- 2012-10-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01114581. Inclusion in this directory is not an endorsement.